Vildagliptin versus metformin on hepatic steatosis in type 2 diabetic patients.

vildagliptin versus metformin on hepatic steatosis - vildagliptin versus metformin on hepatic steatosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000055121

Enrollment

246

Registered

2024-07-30

Start date

2024-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TYPE 2 DM

Interventions

Vildagliptin Metformin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: T2DM

Exclusion criteria

Exclusion criteria: Severe disease

Design outcomes

Primary

Measure	Time frame
Hepatic steatosis	—

Countries

Africa

Contacts

Public ContactHosam Ahmad

Egypt Ministry of Health and population Tropical and Biomedical Chemistry

hosam.refaei1@gmail.com01000638308

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026